Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Surgical Considerations and Systemic Therapy of Melanoma.

Literature DB >> 31753109

Surgical Considerations and Systemic Therapy of Melanoma.

Adriana C Gamboa¹, Michael Lowe¹, Melinda L Yushak², Keith A Delman³.

Abstract

Recent advances in effective medical therapies have markedly improved the prognosis for patients with advanced melanoma. This article aims to highlight the current era of integrated multidisciplinary care of patients with advanced melanoma by outlining current approved therapies, including immunotherapy, targeted therapy, radiation therapy, and other strategies used in both the adjuvant and the neoadjuvant setting as well as the evolving role of surgical intervention in the changing landscape of advanced melanoma.

Entities: Chemical Disease Gene Mutation Species

Keywords: Adjuvant therapy; Advanced melanoma; Immunotherapy; Neoadjuvant therapy; Targeted therapy

Mesh：

Substances：

Year: 2019 PMID： 31753109 PMCID： PMC6914258 DOI： 10.1016/j.suc.2019.09.012

Source DB: PubMed Journal: Surg Clin North Am ISSN： 0039-6109 Impact factor: 2.741

70 in total

1. Improved survival with ipilimumab in patients with metastatic melanoma.

Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245

2. Cutaneous malignant melanoma incidence and mortality trends in Canada: A comprehensive population-based study.

Authors: Feras M Ghazawi; Janelle Cyr; Rami Darwich; Michelle Le; Elham Rahme; Linda Moreau; Elena Netchiporouk; Andrei Zubarev; Osama Roshdy; Steven J Glassman; Denis Sasseville; Ivan V Litvinov
Journal: J Am Acad Dermatol Date: 2018-08-06 Impact factor: 11.527

3. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

Authors: Rodabe N Amaria; Peter A Prieto; Michael T Tetzlaff; Alexandre Reuben; Miles C Andrews; Merrick I Ross; Isabella C Glitza; Janice Cormier; Wen-Jen Hwu; Hussein A Tawbi; Sapna P Patel; Jeffrey E Lee; Jeffrey E Gershenwald; Christine N Spencer; Vancheswaran Gopalakrishnan; Roland Bassett; Lauren Simpson; Rosalind Mouton; Courtney W Hudgens; Li Zhao; Haifeng Zhu; Zachary A Cooper; Khalida Wani; Alexander Lazar; Patrick Hwu; Adi Diab; Michael K Wong; Jennifer L McQuade; Richard Royal; Anthony Lucci; Elizabeth M Burton; Sangeetha Reddy; Padmanee Sharma; James Allison; Phillip A Futreal; Scott E Woodman; Michael A Davies; Jennifer A Wargo
Journal: Lancet Oncol Date: 2018-01-18 Impact factor: 41.316

4. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Authors: Jeffrey S Weber; Sandra P D'Angelo; David Minor; F Stephen Hodi; Ralf Gutzmer; Bart Neyns; Christoph Hoeller; Nikhil I Khushalani; Wilson H Miller; Christopher D Lao; Gerald P Linette; Luc Thomas; Paul Lorigan; Kenneth F Grossmann; Jessica C Hassel; Michele Maio; Mario Sznol; Paolo A Ascierto; Peter Mohr; Bartosz Chmielowski; Alan Bryce; Inge M Svane; Jean-Jacques Grob; Angela M Krackhardt; Christine Horak; Alexandre Lambert; Arvin S Yang; James Larkin
Journal: Lancet Oncol Date: 2015-03-18 Impact factor: 41.316

5. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.

Authors: Michael A Henderson; Bryan H Burmeister; Jill Ainslie; Richard Fisher; Juliana Di Iulio; B Mark Smithers; Angela Hong; Kerwin Shannon; Richard A Scolyer; Scott Carruthers; Brendon J Coventry; Scott Babington; Joao Duprat; Harald J Hoekstra; John F Thompson
Journal: Lancet Oncol Date: 2015-07-20 Impact factor: 41.316

6. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors: Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal: N Engl J Med Date: 2012-02-23 Impact factor: 91.245

7. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Authors: Robert H I Andtbacka; Howard L Kaufman; Frances Collichio; Thomas Amatruda; Neil Senzer; Jason Chesney; Keith A Delman; Lynn E Spitler; Igor Puzanov; Sanjiv S Agarwala; Mohammed Milhem; Lee Cranmer; Brendan Curti; Karl Lewis; Merrick Ross; Troy Guthrie; Gerald P Linette; Gregory A Daniels; Kevin Harrington; Mark R Middleton; Wilson H Miller; Jonathan S Zager; Yining Ye; Bin Yao; Ai Li; Susan Doleman; Ari VanderWalde; Jennifer Gansert; Robert S Coffin
Journal: J Clin Oncol Date: 2015-05-26 Impact factor: 44.544

Surgical Considerations and Systemic Therapy of Melanoma.

1. Improved survival with ipilimumab in patients with metastatic melanoma.

2. Cutaneous malignant melanoma incidence and mortality trends in Canada: A comprehensive population-based study.

3. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

4. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

5. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.

6. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

7. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

8. Melanoma adrenal metastasis: natural history and surgical management.

9. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma?

10. Surgical resection for melanoma metastatic to the gastrointestinal tract.

1. Brachytherapy in a Single Dose of 10Gy as an "in situ" Vaccination.